Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed later-stage tilt small index

Wiskott-Aldrich Syndrome: later-stage trial registry

A small indexed set (5 trials) with no open enrollment listed right now.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · none currently recruiting · #3,391 of 28,707 conditions by registered trial count

Wiskott-Aldrich Syndrome: 5 US clinical trials tracked, none currently recruiting.

Wiskott-Aldrich Syndrome is the subject of 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Bio Products Laboratory, running 1 of these trials.

Enrollment posture brief

Registry condition wiskott-aldrich-syndrome

OPEN 0 | RECR 0% | LATE 2 | EARLY 1 | RANK #3391 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Wiskott-Aldrich Syndrome (th…0%
Open-enrollment share among volume-matched conditions near Wiskott-Aldrich Syndrome

Wiskott-Aldrich Syndrome has no open enrollment in this registry pull (5 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Wiskott-Aldrich Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Wiskott-Aldrich Syndrome is recruiting below its size-band peers.

    0 of 5 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Wiskott-Aldrich Syndrome research.

    Bio Products Laboratory accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Wiskott-Aldrich Syndrome trials plan to enrol fewer than 100 people.

    Median target enrolment is 50 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.

  4. Wiskott-Aldrich Syndrome research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21Phase 32

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 2

Named interventions

Most-linked intervention names on Wiskott-Aldrich Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Gammaplex (Intravenous immunoglobulin) Biological
1 trials
OTL-103 Genetic
1 trials
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan Drug
1 trials
Fludarabine phosphate 40 mg Drug
1 trials
Stem Cell Transplantation Biological
1 trials
Alemtuzumab 0.3 mg Drug
1 trials
Busulfan Drug
1 trials
Cyclophosphamide Drug
1 trials

US sites by state

Facility locations filed on Wiskott-Aldrich Syndrome trials. A trial with sites in several states counts in each.

Georgia 3 trials
Missouri 2 trials
Minnesota 2 trials
Illinois 2 trials
Florida 2 trials
Washington 1 trials
Texas 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Wiskott-Aldrich Syndrome page

5 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Wiskott-Aldrich Syndrome trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Bio Products Laboratory sponsors the most Wiskott-Aldrich Syndrome trials on record, review their full trial history before evaluating a specific study. See Bio Products Laboratory's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Wiskott-Aldrich Syndrome condition card totals 5 registered trials; most-linked intervention Gammaplex (Intravenous immunoglobulin); top US site state Georgia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.